Chairs:

Real world experience and clinical aspects of MPN treatments

H. Gisslinger, R. Kušec

11:00 - 11:15

European PV guidelines by comparison. Where are we going?

R. Kušec

11:15 - 11:30

MIND – MPN database of the Czech Leukemia Study Group

M. Doubek

11:30 - 11:45

Polish experience with ropeginterferon alfa-2b in patients suffering from polycythemia vera

T. Sacha

11:45 - 12:00

A potentially new thromboembolic event scoring system in polycythemia vera patients: an audit of the Hungarian Philadelphia negative chronic myeloproliferative neoplasia register

M. Egyed

12:00 - 12:15

Essential thrombocythemia: what comes after hydroxyurea, pegylated interferon and anagrelide?

A. Rüfer

12:15 - 12:30

When to use ropeginterferon alfa-2b in patients with polycythemia vera? Real world evidence from the Clinical Institute from Bucharest, Romania

I. Ursuleac

12:30 - 12:45

Aiming for disease modification in PV – my personal experience

D. Lechner-Radner

12:45 - 13:00

Discussion

13:00 - 14:00

Open discussion at speakers‘ corner

Kindly supported by AOP Health